Clinical Study to Assess Efficacy and Safety of LN-145 (Autologous Centrally Manufactured Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types
MD Anderson Study Status
Aldesleukin, Autologous Tumor Infiltrating Lymphocytes LN-145, Cyclophosphamide, Fludarabine, Fludarabine Phosphate
This phase II trial studies how well autologous tumor infiltrating lymphocytes LN-145 (LN-145) works in treating patients with ovarian cancer, osteosarcoma, or other bone and soft tissue sarcomas that do not respond to treatment (refractory) or that has come back (relapsed). LN-145 is made by collecting and growing specialized white blood cells (called T-cells) that are collected from the patient's tumor. The T cells may specifically recognize, target, and kill the tumor cells.
Information and next steps
Bone Sarcoma, Dedifferentiated Chondrosarcoma, Giant Cell Tumor of Bone, Malignancy in Giant Cell Tumor of Bone, Ovarian Carcinosarcoma, Platinum-Resistant Ovarian Carcinoma, Recurrent Osteosarcoma, Refractory Osteosarcoma, Refractory Ovarian Carcinoma, Soft Tissue Sarcoma, Undifferentiated High Grade Pleomorphic Sarcoma of Bone
Gynecologic Oncology & Reproductive Medicine
For general questions about clinical trials: